4/A

PRIMARY DOCUMENT

Company: Cartesian Therapeutics, Inc.
Filed: July 10, 2017
Period of Report: June 15, 2017
Accession Number: 0001638599-17-000690

View Document ↗ View on SEC.gov ↗